Aligos Therapeutics Signals Potential Tender Offer Activity

TL;DR

**Aligos Therapeutics is gearing up for a tender offer, watch for details on share buybacks or acquisitions.**

AI Summary

Aligos Therapeutics, Inc. filed an 8-K on January 25, 2024, indicating it is engaging in "Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." This specific filing suggests the company is preparing for a tender offer, which could involve buying back its own shares or acquiring another company. For investors, this matters because a tender offer can significantly impact share price and ownership structure, potentially offering a premium for shares or diluting existing holdings depending on the nature of the offer.

Why It Matters

This filing signals Aligos Therapeutics is preparing for a tender offer, which could lead to a significant change in its capital structure or ownership, directly impacting shareholder value.

Risk Assessment

Risk Level: medium — The specific nature and terms of the potential tender offer are unknown, introducing uncertainty regarding its impact on shareholders.

Analyst Insight

A smart investor would closely monitor Aligos Therapeutics' subsequent filings for details on the tender offer, as it could present an opportunity to sell shares at a premium or indicate a strategic shift.

Key Players & Entities

• Aligos Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 25, 2024 (date) — date of earliest event reported
• Rule 13e-4(c) (other) — SEC rule governing pre-commencement communications for tender offers
• ALGS (other) — trading symbol for Aligos Therapeutics, Inc.
• The Nasdaq Stock Market LLC (other) — exchange where ALGS common stock is registered

Forward-Looking Statements

• Aligos Therapeutics will announce the specific terms of a tender offer. (Aligos Therapeutics, Inc.) — high confidence, target: Q1 2024
• The tender offer will involve a share buyback program. (Aligos Therapeutics, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALGS The Nasdaq
• $2.10 — exercise price equal to or greater than $2.10. Eligible participants will be permit

Filing Documents

• d115183d8k.htm (8-K) — 29KB
• d115183dex991.htm (EX-99.1) — 5KB
• 0001193125-24-014769.txt ( ) — 160KB
• algs-20240125.xsd (EX-101.SCH) — 3KB
• algs-20240125_lab.xml (EX-101.LAB) — 18KB
• algs-20240125_pre.xml (EX-101.PRE) — 11KB
• d115183d8k_htm.xml (XML) — 3KB

01

Item 8.01 Other Events. On January 25, 2024, Aligos Therapeutics, Inc. (the "Company") announced that certain eligible employees of the Company and its affiliates and the members of the Company's board of directors (the "Board"), will be invited to participate in a voluntary, one-time opportunity to exchange certain outstanding options for replacement options (the "Replacement Options") pursuant to an option exchange program (the "Option Exchange Program"). Options eligible for exchange (the "Eligible Options") are those options that (i) were granted under the Company's 2020 Incentive Award Plan; (ii) are held by an employee or director of Aligos or its subsidiaries resident in the United States or Switzerland as of the replacement option grant date; and (iii) have an exercise price equal to or greater than $2.10. Eligible participants will be permitted to exchange Eligible Options for Replacement Options covering a lesser number of shares, calculated in accordance with specified exchange ratios, and subject to a new vesting schedule. The criteria for eligible participants and other terms of the Option Exchange Program are still being finalized and are subject to approval by the Board, and will be announced in a Tender Offer Statement on Schedule TO in connection with the commencement of the Option Exchange Program. Attached as Exhibit 99.1 and incorporated by reference herein is an email communication regarding the proposed Option Exchange Program that was sent to Company employees on January 25, 2024. The communication does not constitute an offer to holders of the Company's outstanding stock options to exchange those stock options for Replacement Options. The Option Exchange Program has not yet commenced and will only be made pursuant to the terms and conditions set forth in the Tender Offer Statement on Schedule TO, including the Offer to Exchange, and other related materials filed with the Securities and Exchange Commission and sent to eligible partici

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Communication to Eligible Participants. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ALIGOS THERAPEUTICS, INC. Date: January 25, 2024 By: /s/ Lesley Ann Calhoun Lesley Ann Calhoun Executive Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR